drugset / Trial / NCT01352416
Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery
Phase 3
Terminated
15 enrolled
Corewell Health East
Beaumont Foundation of America · collabGilead Sciences · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is to show that ranolazine is a safe, viable and potent alternative for post-operative atrial fibrillation suppression in patients undergoing cardiac surgery
Timeline
- Start
- 2010-09
- Primary completion
- 2012-11
- Completion
- 2012-11
Outcome
Outcome not reported
Stopped (Enrollment): “lack of enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranolazine | Small molecule | 1000 mg | — |